Endovascular Treatment of Renal Artery Thrombosis in Living-Donor Kidney Transplant Recipient With Severe COVID-19 Disease

J Endovasc Ther. 2022 Dec;29(6):966-970. doi: 10.1177/15266028211068756. Epub 2022 Jan 7.

Abstract

Purpose: Coronavirus disease 2019 (COVID-19) patients have a higher prevalence of micro-and macrovascular thrombotic events. However, the underlying mechanism for the increased thrombotic risk is not completely understood. Solid organ transplant recipients infected with SARS-CoV-2 may have an exponential increase in thrombotic risk and the best management strategy is unknown.

Case report: A female kidney transplant recipient presented with allograft's renal artery thrombosis after a recent COVID-19 infection. Due to the risk of kidney failure or exclusion, catheter directed thrombolysis was performed. Residual thrombus was excluded using an endoprosthesis with an excellent result. There were no adverse events and kidney function improved.

Conclusion: This paper reports the endovascular treatment of renal artery thrombosis in a living-donor kidney transplant recipient with severe COVID-19 disease.

Keywords: COVID-19; catheter-directed thrombolysis; kidney transplant; renal artery thrombosis.

Publication types

  • Case Reports

MeSH terms

  • COVID-19*
  • Female
  • Humans
  • Kidney Transplantation* / adverse effects
  • Living Donors
  • Renal Artery / diagnostic imaging
  • Renal Artery / surgery
  • SARS-CoV-2
  • Thrombosis* / diagnostic imaging
  • Thrombosis* / etiology
  • Thrombosis* / surgery
  • Treatment Outcome